Psychedelic-Assisted Therapy

Overview

"Psychedelics" is an umbrella term for a group of compounds that produce profound alterations in consciousness, perception, and emotion. The two most relevant for psychiatric treatment in 2026 are MDMA (studied for PTSD) and psilocybin (studied for depression). Others under investigation include LSD, DMT, ibogaine, and mescaline.

The term "psychedelic-assisted therapy" (PAT) refers to the model under study: the drug is given in a carefully prepared clinical setting alongside structured psychotherapy, usually with preparation sessions beforehand and integration sessions afterward. The drug is one part of a much larger process, not a pill you take and go home.

Why this is being studied

Standard treatments for depression and PTSD help many people, but not everyone. Current first-line treatments leave roughly one-third of patients still symptomatic after multiple adequate trials. For those with severe, chronic, or treatment-resistant illness, better options are genuinely needed.

Psychedelic-assisted therapy is being studied because early trials have shown something unusual: rapid and durable improvement after just one or two sessions, often in patients who haven't responded to years of other treatment. Whether those findings hold up under rigorous Phase 3 scrutiny is the question that's currently being answered, with mixed results so far.

The mechanisms are different from standard antidepressants. Rather than modulating neurotransmitters day-by-day over weeks, the model is that a small number of deeply altered-consciousness experiences — when combined with therapy — can produce lasting psychological reorganization. That's a big claim, and the evidence base is still being built.

MDMA-assisted therapy for PTSD

What MDMA is

MDMA (3,4-methylenedioxymethamphetamine, sometimes called "ecstasy" or "molly" in recreational contexts) is a synthetic compound that increases serotonin, norepinephrine, and dopamine while also triggering release of oxytocin and related social-bonding neurochemicals. It's often described as an empathogen — a compound that heightens empathy and feelings of social connection.

Why this is interesting for PTSD

Something specific happens under MDMA that may be useful for trauma therapy. Patients appear to be able to revisit traumatic memories without becoming as overwhelmed as they normally would — sometimes described as a wider "window of tolerance" for difficult material. This allows trauma processing to happen in therapy in a way that would otherwise be too destabilizing.

Animal studies back this up: MDMA appears to enhance fear extinction learning, which is the mechanism that helps trauma lose its emotional charge over time.

The evidence

Two Phase 3 trials (Mitchell 2021 and Mitchell 2023, originally published in Nature Medicine) showed large effects:

• In the first trial, after 18 weeks, 71% of MDMA-assisted therapy participants no longer met DSM-5 criteria for PTSD, compared to 48% in placebo-plus-therapy
• The second trial confirmed similar magnitude of effect
• These were large, significant reductions in standard PTSD rating scales

What happened with the FDA

Lykos (the company that ran the trials) is continuing to work with the FDA and is expected to run an additional Phase 3 trial before resubmitting. Approval timeline is uncertain and likely several years away at minimum.

Psilocybin-assisted therapy for depression

What psilocybin is

Psilocybin is the main psychoactive compound in certain species of mushrooms (sometimes called "magic mushrooms" in recreational contexts). In the body it's converted to psilocin, which acts primarily on serotonin receptors — specifically the 5-HT2A receptor — producing a profound but time-limited alteration of consciousness typically lasting 4–6 hours.

Why this is interesting for depression

Unlike daily antidepressants, the model with psilocybin-assisted therapy is that a single high-dose session (plus preparation and integration therapy) can produce weeks to months of improvement. The experience itself is central: patients report often-profound shifts in how they relate to themselves, to difficult memories, or to their sense of meaning and purpose.

There's genuine biological plausibility too. Psilocybin appears to temporarily loosen rigid patterns of brain activity that are often associated with depression, and there's evidence it promotes neuroplasticity — the brain's ability to form new connections.

The evidence

Several randomized controlled trials have shown meaningful benefit:

• Carhart-Harris 2021 compared two doses of psilocybin against six weeks of daily escitalopram (a standard SSRI) in treatment-resistant depression. 70% of the psilocybin group showed response vs. 48% of the escitalopram group.
• Goodwin 2022 tested psilocybin in treatment-resistant depression, with a 37% response rate at 25 mg vs. 18% at the low-dose control.
• Raison 2023 tested single-dose psilocybin in major depressive disorder with significantly reduced depression scores sustained through 6 weeks.
• Davis 2021 demonstrated 71% response and 58% remission at 1-4 weeks post-treatment in major depression.

Current status

Compass Pathways, the company leading psilocybin development, is in the final stages of Phase 3 trials for treatment-resistant depression. As of late 2025, they were planning a rolling submission to the FDA with a possible approval decision in late 2026 or early 2027. Usona Institute is running a separate program for major depressive disorder (not treatment-resistant).

If approved, psilocybin would become the first FDA-approved psychedelic for a psychiatric indication in the United States.

Current regulatory status (early 2026)

If you're considering psychedelic therapy

I'm certified in psychedelic-assisted therapy and I'm broadly supportive of this research direction. I also think patients considering these treatments right now deserve a very honest conversation about what's actually available and what the real risks are.

What's currently available legally

• Clinical trials for MDMA, psilocybin, and other compounds. These are the safest legal option but enrollment is selective and geographically limited.
• Oregon and Colorado state-regulated psilocybin services. Not "medical treatment" in the FDA sense; administered by licensed facilitators rather than medical professionals.
• Ketamine-assisted therapy is the closest currently available medical analog — legal, FDA-approved (as Spravato), and shares some mechanisms with classical psychedelics. See the ketamine page for details.

What I'd caution against

What's reasonable to expect

If you're thinking about psychedelic therapy, the most honest framing I can offer is this: the research is promising but not yet at a place where these treatments are routinely available. If you're struggling now and looking for options, the better path usually is to explore treatments that are currently available and effective — TMS, ECT, ketamine, and good therapy — while watching the psychedelic research landscape as it develops.

How this is different from ketamine

Ketamine and classical psychedelics are often grouped together in popular discussion, but they're importantly different:

• Ketamine is an NMDA-receptor antagonist (plus some opioid and AMPA activity). Classical psychedelics (psilocybin, LSD, DMT, MDMA) primarily work on serotonin receptors.
• Ketamine is FDA-approved (as Spravato) and widely available. MDMA and psilocybin are not yet FDA-approved.
• Ketamine is typically given in a series of 6 infusions over 2–3 weeks with ongoing maintenance. Psychedelic-assisted therapy protocols typically involve just 1–3 sessions over several months with intensive preparation and integration.
• Ketamine's subjective experience lasts ~1 hour; psilocybin sessions last 4–6 hours, MDMA sessions 6–8 hours. This changes the therapy logistics substantially.
• Ketamine can cause dissociation; classical psychedelics produce a different subjective quality — more emotionally immersive, more symbolic, often with visual phenomena.

Both categories of treatment share some features — rapid onset compared to standard antidepressants, a role for the subjective experience — but the differences matter clinically.

Common questions

Is this just recreational drug use rebranded as medicine?

The short answer is no, and the difference really matters. Therapeutic protocols involve pre-screening, structured preparation sessions, medical supervision during the experience, and integration sessions afterward — all of which are absent in recreational use. The therapeutic setting (what gets called "set and setting") is a big part of what makes these treatments potentially effective, and a big part of what makes them safer in research vs. recreational contexts.

If MDMA didn't get FDA approval, does that mean it doesn't work?

Not quite. The FDA's concerns were mostly about how the trials were run, not whether MDMA itself has an effect on PTSD symptoms. The clinical effects in the Phase 3 trials were large. What the FDA wanted was more rigorous evidence that those effects were specifically attributable to the drug rather than to functional unblinding, therapist expectations, or other factors that can inflate effect sizes in trials of psychoactive compounds.

Should I travel somewhere to try these treatments?

Honestly — I'd generally advise against it at this point unless you're enrolling in a formal clinical trial. "Retreat" programs abroad vary widely in quality; medical screening may be inadequate; the absence of oversight and accountability means problems can be hard to address; and you're often far from your usual medical support. Waiting a couple of years for proper FDA-approved treatment in a regulated setting is usually the safer path, even when the wait feels frustrating.

Can I get into a clinical trial?

Possibly. ClinicalTrials.gov is searchable by condition and location. Major academic centers (Johns Hopkins, NYU, UCSF, Mount Sinai, among others) have active psychedelic research programs. Eligibility is usually strict — severe illness, specific diagnosis, limited other medical conditions, geographic proximity to the research site.

What if my other treatments aren't working and I can't wait?

Let's have a conversation. Ketamine and ECT are both currently available, well-studied, and often highly effective for treatment-resistant depression. Newer TMS protocols have broadened substantially. There may be options that would work for you now rather than in two to three years.

Get in touch

The Prisma Health Neuromodulation Program doesn't currently offer MDMA or psilocybin therapy — these aren't yet FDA-approved. But if you're trying to think through your options, figure out whether a clinical trial might fit, or evaluate other evidence-based treatments that are currently available, we can help.